Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2017

  • ID: 4432176
  • Report
  • 66 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Otsuka Holdings Co Ltd
  • Vaximm AG
  • MORE
Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2017'; Wilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 16 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Wilms Tumor Protein (WT33 or WT1) - Wilms tumor protein is a protein that is encoded by the WT1 gene. It plays an important role in cellular development and cell survival. It plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. It regulates the expression of numerous target genes, including EPO.

The report 'Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2017' outlays comprehensive information on the Wilms Tumor Protein (WT33 or WT1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 6, 1 and 2 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome, Glioblastoma Multiforme (GBM), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Ovarian Cancer, Solid Tumor, Malignant Glioma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Hematological Tumor, Leukemias, Non-Small Cell Lung Cancer, Pancreatic Cancer, Adrenal Gland Cancer, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Carcinoma, High-Grade Glioma, Lung Cancer, Lymphoma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Ocular Melanoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Small Intestine Cancer, Soft Tissue Sarcoma, Testicular Cancer, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1)
  • The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein (WT33 or WT1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein (WT33 or WT1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Otsuka Holdings Co Ltd
  • Vaximm AG
  • MORE
Introduction

Wilms Tumor Protein (WT33 or WT1) - Overview

Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development

GlaxoSmithKline Plc

Inovio Pharmaceuticals Inc

Otsuka Holdings Co Ltd

Sellas Life Sciences Group Ltd

Sumitomo Dainippon Pharma Co Ltd

Vaximm AG

Wilms Tumor Protein (WT33 or WT1) - Drug Profiles

elatipepimut-S + adegrapepimut-S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galinpepimut-S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2130579A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCV-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXM-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WT-2725 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WT-4869 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Wilms Tumor Protein (WT33 or WT1) - Dormant Products

Wilms Tumor Protein (WT33 or WT1) - Discontinued Products

Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones

Featured News & Press Releases

Nov 01, 2017: Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regenerons PD-1 Inhibitor

Oct 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer

Sep 14, 2017: SELLAS Galinpepimut-S Induces Specific, Robust and Durable Immune Responses in Patients With High-Risk Multiple Myeloma - Correlated With Clinical Benefit

Sep 05, 2017: VAXIMM Presents Preclinical Results For VXM06 Presented at Third CRI-CIMT-EATI-AACR Conference

Jul 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Myelodysplastic Syndrome

May 18, 2017: Sumitomo Dainippon Pharma to Present Clinical Data on WT-2725 at ASCO 2017

Mar 30, 2017: VAXIMM to present preclinical data on VXM06m at AACR Annual Meeting 2017

Mar 01, 2017: SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients

Feb 27, 2017: Inovio’s SynCon WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy

Dec 06, 2016: Boston Biomedical Announces First Clinical Data for Investigational WT1 Cancer Peptide Vaccine, DSP-7888, at ASH Annual Meeting & Exposition

Dec 01, 2016: VAXIMM Presents Preclinical Data on VXM-06 at EORTC-NCI-AACR Symposium

Nov 04, 2016: Sumitomo Dainippon Pharma Announces the Data of an Investigational WT1 Cancer Peptide Vaccine, DSP-7888 will be Presented at the ASH 2016

Oct 19, 2016: SELLAS Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy OfficeR

Oct 13, 2016: SELLAS Life Sciences Announces Positive Interim Phase II Results from its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients

Oct 03, 2016: SELLAS Life Sciences Appoints Industry Experts to Support Advancement of Cancer Therapeutics Pipeline

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by GlaxoSmithKline Plc, H2 2017

Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Pipeline by Otsuka Holdings Co Ltd, H2 2017

Pipeline by Sellas Life Sciences Group Ltd, H2 2017

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017

Pipeline by Vaximm AG, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc
  • Otsuka Holdings Co Ltd
  • Sellas Life Sciences Group Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Vaximm AG
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll